Tolebrutinib, a brain-penetrant and bioactive Bruton tyrosine kinase inhibitor that modulates persistent immune activation ...

Tolebrutinib is an oral, brain-penetrant, and bioactive Bruton’s tyrosine kinase inhibitor that modulates peripheral ...

A Cleveland Clinic-led clinical trial of tolebrutinib, an investigational oral Bruton's tyrosine kinase inhibitor, a group of ...

Results of the Phase III HERCULES trial suggest the first potential treatment option for a form of multiple sclerosis.

Delve into the kinase inhibitors' diverse landscape, from cancer breakthroughs to autoimmune disease innovations.

Blood cancer patients who receive a type of anti-cancer therapy should continue to take the drug while having COVID-19 ...

Emerging treatments like tyrosine kinase inhibitors (TKIs) offer promise by targeting complementary pathways in angiogenesis and providing sustained-release options to reduce injection frequency.

The phosphoinositide 3-kinase (PI3K) pathway is a crucial signal transduction system linking the activation of receptor tyrosine kinases (RTKs), G protein-coupled receptors (GPCRs) and oncogenes ...

A number of recent trials have explored potential strategies for using immunotherapy in chronic lymphocytic leukemia (CLL).

Inhibikase Therapeutics, Inc.’s IKT share price has dipped by 14.13%, which has investors questioning if this is right time ...